Abstract: A pillar-shaped honeycomb structure body of a honeycomb structure includes a circumferential cell structure, a central cell structure and a boundary wall therebetween. On a surface orthogonal to the cells there are a circumferential reinforcing region having the partition wall thicker than a basic partition wall thickness in the circumferential cell structure and existing outside a range of a distance from a centroid of the surface; and at least one of a first boundary reinforcing region having the partition wall thicker than the basic partition wall thickness and existing in a range of a distance from the centroid within a range of the circumferential cell structure and a second boundary reinforcing region having the partition wall thicker than a basic partition wall thickness in the central cell structure and existing outside of a range of a distance from the centroid within a range of the central cell structure.

Abstract: A honeycomb structure including: a pillar-shaped honeycomb structure body, the honeycomb structure body being configured to include a circumferential portion and a central portion, wherein a shape of the cells is a triangle or a hexagon having at least one symmetrical axis, in the shape of the cells, a number of the symmetrical axes is defined as A, a number of vertices of the shape of the cells is defined as N, and a value shown in a following Equation (1) is defined as 0, an arrangement direction of the cells in the circumferential portion is inclined in a range of ??15° to ?+15° with respect to an arrangement direction of the cells in the central portion.

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract: A ceramic porous body comprising: skeleton portions; and pore portions formed between the skeleton portions, the pore portions being capable of allowing a fluid to flow therethrough. In the ceramic porous body, the pore portions satisfy the following equations (1) and (2) in a cross section parallel to a flow direction of the fluid; L1/L2?0.92??(1), and L1+L2?27 ?m??(2) in which L1 is an average length of the pore portions in the flow direction of the fluid; and L2 is an average length of the pore portions in a direction orthogonal to the flow direction of the fluid.

Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

Abstract: A ceramic porous body comprising: skeleton portions including an aggregate and at least one binding material; and pore portions formed between the skeleton portions, the pore portions being capable of allowing a fluid to flow therethrough. In the ceramic porous body, the pore portions have a pore volume ratio of pores having a pore diameter of from 1 to 10 ?m, of 45% or more, and a ratio of a contact area between the aggregate and the binding material to a surface area of the binding material of from 20 to 60%.

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.